Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate Crohn's Disease.
Latest Information Update: 19 Aug 2015
At a glance
- Drugs GLPG 1205 (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Galapagos NV
- 30 Jul 2014 New trial record